FDA Restricts Obeticholic Acid Over Serious Liver Injury Risk FDA Restricts Obeticholic Acid Over Serious Liver Injury Risk

Obeticholic acid is now contraindicated in patients with primary biliary cholangitis and advanced cirrhosis, following reports of serious liver injury leading to liver decompensation or liver failure.News Alerts
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Gastroenterology News Alert Source Type: news